Also trades as: LFMDP (NASDAQ) · $vol 0M
LFMD NASDAQ
LifeMD, Inc.
1W: -7.7%
1M: -10.8%
3M: -44.2%
YTD: -21.5%
1Y: -59.4%
3Y: -50.2%
5Y: -60.2%
$2.74
-0.11 (-3.86%)
Weekly Expected Move ±9.3%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (53)
Bank of America Corp DE Buys New Stake in LifeMD, Inc. $LFMD
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
UPDATE - LifeMD Reports Second Quarter 2026 Results
LifeMD Reports Second Quarter 2026 Results
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
Hims & Hers Expands Integrated Health Access via Platform Expansion
Is CAH Becoming the Backbone of US Healthcare Infrastructure?
LifeMD to Participate in Upcoming Investor Conferences
Lifemd reaffirms 2026 guidance of $220M-$230M revenue and $12M-$17M adjusted EBITDA as it targets $250M+ run-rate revenue by Q4
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LifeMD (LFMD) Q1 2026 Earnings Transcript
12 Health Care Stocks Moving In Wednesday's After-Market Session
Earnings Scheduled For May 6, 2026
LifeMD Reports First Quarter 2026 Results
Hims & Hers Expands DTC Platform to Broaden Access to Personal Care
Amazon GLP-1 Program Pressures Hims & Hers Stock
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
Novo to sell Wegovy subscriptions on Hims, LifeMD, and others
LifeMD, Inc. 8.875% CUM PFD A declares $0.5547 dividend
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
LifeMD appoints Atul Kavthekar as CFO
LifeMD appoints new CFO; shares up
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
This Upstart Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
LifeMD outlines $250M+ annualized revenue run rate target by Q4 2026 amid record GLP-1 demand and expanded partnerships
LifeMD: Q4 Earnings Insights
LifeMD rises on Q4 2025 beats, 2026 revenue guidance midpoint above consensus
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
12 Health Care Stocks Moving In Monday's After-Market Session
LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD Reports Fourth Quarter and Full Year 2025 Results
Here are the major earnings after the close Monday
Earnings Scheduled For March 9, 2026
Earnings Outlook For LifeMD
LifeMD to Participate in Two Investor Conferences During March
LifeMD to Participate in Two Investor Conferences During March
Hims & Hers Expands Digital Health and Global Platform Strategy
LifeMD: Still My Favorite Bargain On The Market
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
LifeMD: Pure Telehealth Play With In-House Pharmacy Integration
Kuehn Law Encourages Investors of LifeMD, Inc. to Contact Law Firm
LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Moderate Buy” by Brokerages
Kuehn Law Encourages Investors of LifeMD, Inc. to Contact Law Firm
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026